Browse All Grants
20,252 grants found
Showing 1,921 – 1,940 of 20,252 grants
Tumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumors
PROJECT SUMMARY Adoptive cell transfer using tumor-specific T cells is a promising option for cancer treatment and the most powerful tumor-killing effector T cells are CD8+ type-1...
Molecular and structural mechanisms of mTORC1 regulation in cancer
PROJECT SUMMARY The mechanistic Target of Rapamycin Complex 1 (mTORC1) is master regulator of cell growth and metabolism. Dysregulation of mTORC1 is observed in sporadic and famili...
Culture of tumor versus normal cells
PROJECT SUMMARY Background: Mammalian models of cancer have been instrumental in the development of many targeted therapies. It is, however, difficult to establish these models, su...
Meaning-Centered Psychotherapy to Meet Palliative Care Needs of Cancer Caregivers
PROJECT SUMMARY In 2020, 53 million people in the U.S. served as family caregivers, the partners, relatives, and friends who provide assistance (i.e., physical, emotional) to patie...
Dissecting the Sox2-orchestrated transcriptional network that governs immune resistance in tumor initiating cells
PROJECT SUMMARY The treatments for various squamous cell carcinomas (SCCs), such as SCCs of the head and neck, have been revolutionized by the development of immunotherapies. Howev...
Elucidation of hypoxia-induced metastatic reprogramming through the regulation of KDM8 function in pancreatic cancer
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies. Full transcriptome defines clinically relevant “subtypes” of disease and the basal-like subty...
Decoding 41BB-specific dysfunction programs in cellular immunotherapies for cancer
PROJECT SUMMARY This proposal aims to elucidate the molecular circuitry that limits the efficacy of chimeric antigen receptor (CAR)-engineered T cells. CARs are synthetic proteins...
ROLES AND MECHANISMS OF TERTIARY LYMPHOID STRUCTURES IN ANTI-TUMOR IMMUNITY
PROJECT SUMMARY Tertiary lymphoid structures (TLS) are T and B lymphocytes in aggregation with antigen presenting cells, fibroblasts, and high endothelial venules observed in some...
MYCN drives a druggable SUMOylation program in neuroblastoma
Project Summary: High-risk neuroblastoma (NB) is responsible for ~15% of pediatric cancer-related deaths, with nearly half of these characterized by MYCN amplification. The additio...
The Role of the Tumor Suppressor ARID1A in R loop Homeostasis and Tumor Immunity
PROJECT SUMMARY Cancer immunotherapy is the practice of harnessing the activity of the immune system to combat cancer. Immune checkpoint blockade (ICB) is a type of cancer immunoth...
Combined targeting of synthetic lethal partners in RB1-deficient cells
Abstract RB1 is a tumor suppressor gene that is frequently mutated in various tumors, including retinoblastomas, small cell lung cancers, triple-negative breast cancers, prostate c...
Delineating the myeloid-centric immunosuppressive crosstalk as targets for prognosis and therapy in neuroendocrine tumors
Project Summary / Abstract Neuroendocrine tumors (NETs) that are clinically and pathologically similar display significant differences in disease progression, therapeutic response,...
Developing humanized Nut Carcinoma mouse model for developing NUTM1 targeted therapies.
Title: Developing humanized Nut Carcinoma mouse model for developing NUTM1 targeted therapies. Project Summary: NUT carcinoma (NC) is a highly aggressive cancer with no effective t...
SR-A as a therapeutic target in breast cancer
ABSTRACT Tumor-associated macrophages are critical regulators of tumor development, progression, and metastasis. Factors in the tumor microenvironment induce tumor-associated macro...
Targeting the Androgen Receptor to Sensitize Bladder Cancer to Immune Check Point Blockade.
PROJECT SUMMARY: “Targeting the Androgen Receptor in Bladder Cancer to Enhance Sensitivity to Immune Checkpoint Blockade”. Up to 70-80% of patients with bladder cancer demonstrate...
Development of a new class of EZH2 inhibitors in ERa-negative breast cancer.
PROJECT SUMMARY/ABSTRACT The histone methyltransferase (HMTase) EZH2 was proved to drive malignant phenotypes in various types of cancer cells, including the estrogen receptor a-ne...
Spatial Mapping of Phospholipid Biosynthesis in Brain Tumors
PROJECT SUMMARY Glioblastomas (GBMs) are malignant primary brain tumors in adults. Standard of care involves maximal safe surgical resection, radiation, and chemotherapy with temoz...
Metabolic adaptations in melanoma brain metastasis
ABSTRACT Melanoma brain metastasis (MBM) is a deadly, poorly understood consequence of melanoma for which patients need improved treatment options. In integrating proteomics and tr...
Targeting alloantigen presentation in bone marrow to enhance graft-versus-leukemia effects
ABSTRACT Blood cancers account for approximately 10% of all malignancies and allogeneic bone marrow transplantation (BMT) is a preferred curative therapy for these serious conditio...
Repurposing Auranofin As a Novel Notch Pathway Inhibitor for Combinational Ovarian Cancer Therapy
Ovarian cancer is the deadliest gynecologic cancer, with ~20,000 new cases predicted for 2023. Although first-line treatment with a platinum compound and taxane yields a response r...